SAB Biotherapeutics said that the US National Institutes of Health (NIH) is discontinuing the phase 3 ACTIV-2 trial of the company’s SAB-185 for the treatment of Covid-19 because of low hospitalization and death rates in the trial. The National Institutes of Health is therefore stopping enrollment in its Covid-19 phase 3 trial, said the US-based […]
SAB Biotherapeutics, a US biopharma company, said that the first patient in a phase 1b clinical trial of its investigational Covid-19 therapeutic SAB-185 has been dosed. The early-stage trial is assessing the safety and pharmacological activity of SAB-185 in Covid-19 patients. SAB-185, which was generated from a subunit of the SARS-CoV-2 Wuhan strain, has delivered […]